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Abstract  22 
Routine viral load (VL) testing of HIV-infected individuals on antiretroviral therapy (ART) 23 
is used to monitor treatment efficacy. However, due to logistical challenges, 24 
implementation of VL has been difficult in resource-limited settings. The aim of this study 25 
was to evaluate the performance of the SAMBA Semi-Q Test in London, Malawi, and 26 
Uganda. The SAMBA HIV-1 Semi-Q Test can distinguish between patients with VL above 27 
or below 1000 copies/ml. The SAMBA Semi-Q was validated with diluted clinical samples 28 
and blinded plasma samples collected from HIV-1–positive individuals. SAMBA Semi-Q 29 
results were compared with results from the Roche COBAS AmpliPrep/COBAS TaqMan 30 
HIV-1 Test v2.0. Testing of 96 2-10 fold dilutions of four samples containing HIV-1 31 
subtype C as well as 488 samples from patients in the United Kingdom, Malawi, and 32 
Uganda, respectively, yielded an overall accuracy for SAMBA Semi-Q of 99% (95% CI 33 
93.8 – 99.9%) and 96.9% (95% CI 94.9 – 98.3%) respectively compared to Roche. 34 
Analysis of VL data from patients in Malawi and Uganda showed that the SAMBA cut-off 35 
of 1000 copies/ml appropriately distinguished treated from untreated individuals. 36 
Furthermore, analysis of the viral load of 232 patients on ART in Malawi and Uganda 37 
revealed similar patterns for virological control defined as either <1000 copies/ml 38 
(SAMBA cut-off) or <5000 copies/ml (WHO 2010 criterion). This study suggests that 39 
SAMBA Semi-Q has adequate concurrency with the gold standard measurements for viral 40 
load measurement. This test can allow VL monitoring of patients on ART at the point of 41 
care in resource-limited settings. 42 
 43 
Introduction  44 
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There have been steady improvements in scaling-up access to antiretroviral therapy (ART) 45 
in resource-limited countries.(1) There appears to be fewer new infections and AIDS 46 
related deaths have decreased over the past decade. While these achievements are 47 
remarkable, there remains a large unmet need, given that 34 million people are living with 48 
HIV/AIDS globally; most of whom live in sub-Saharan Africa.   49 
 50 
Effective ART not only improves the survival of individuals infected with HIV but also 51 
prevents transmission.(2) The global public health community is therefore committed to 52 
achieving universal access to HIV treatment, with a target of increasing the availability of 53 
ART to 15 million people by the end of 2015.(3) Effective ART suppresses HIV 54 
replication, which is measured through plasma viral load (VL), specifically looking at 55 
potential adherence or treatment failure. VL monitoring prolongs the duration on first-line 56 
regimens by preventing unnecessary switches in ART to more complex and expensive 57 
second-line regimens that result in increased costs and decrease in drug options (4, 5) and 58 
can reduce the delay in switching to second-line drugs or patient counseling, resulting in 59 
better patient outcomes.(6, 7) Studies have shown that sites with VL monitoring have lower 60 
mortality rates (6) and better justification of switching to 2nd line drug regimens than at 61 
sites using only CD4. (4) 62 
 63 
Quantitative VL is the standard of care for patients receiving ART in resource-rich 64 
settings.(8, 9) In resource-poor settings, however, laboratory diagnostics are often only 65 
available at centralized laboratories in major cities due to the complexity of the technology, 66 
the infrastructure and trained personnel required for the tests.(10-12) As ART programs 67 
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have scaled up, there has been a significant effort to decentralize care to local primary 68 
health centers, which have basic services and limited infrastructure. To access VL testing, 69 
peripheral HIV-treatment facilities must transport patient specimens to central laboratories 70 
under optimal conditions within a limited period of time, followed by testing and return of 71 
results. This results in increased costs of service delivery and unacceptable delays in 72 
obtaining test results with consequent losses to follow-up.(13) A priority focus area of the 73 
Treatment 2.0 initiative is therefore the development of affordable, reliable, quality-74 
assured, point-of-care molecular diagnostic platforms. (14) 75 
 76 
SAMBA (Simple Amplification-Based Assay) HIV-1 Semi-quantitative Test (SAMBA 77 
HIV-1 Semi-Q) has been developed as a robust, simple, and relatively rapid point-of-care 78 
test to distinguish between patients with a VL above or below 1000 copies/ml within 90 79 
minutes. The main advantages of SAMBA include visual detection of the result and robust 80 
reagents, which are stable at high temperatures and humidity. All reagents required are 81 
preloaded in single-use, disposable cartridges to ensure that the system is easy to use and to 82 
prevent potential contamination of the laboratory with amplified product. The chemistry is 83 
based on the SAMBA Qualitative Test and can therefore detect all known HIV-1 subtypes. 84 
(15) In consultation with experts in the field of ART provision in low and middle income 85 
countries (LMIC), Médecins Sans Frontières (MSF) concluded that a viral load of 1000 86 
copies/ ml was the level most frequently used as the trigger for clinical intervention. 87 
Furthermore, the threshold for detecting treatment failure was lowered in South Africa in 88 
April 2010 from 5000 to 1000 copies/ml and this has been implemented at various South 89 
African sites. (5, 16). WHO also updated their guidelines in June 2013 and now define 90 
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treatment failure as a persistently detectable viral load exceeding 1000 copies/ml, (8) rather 91 
than 5000 copies/ml. (17) Ideally, patients on ART for more than 6 months with a VL 92 
>1000 copies/ml should be counseled for adherence and retested three months later as per 93 
the WHO guidelines. If the VL remains >1000 copies/ml at follow-up, this may indicate 94 
treatment failure. Therefore, it is important that patients with VL ≥ 1000 copies/ml are 95 
detected by SAMBA Semi-Q. On the other hand, it is also important that individuals with 96 
low VL are not detected as such results may be due to “blips”. VL blips are defined as 97 
intermittent episodes of detectable low VL (50-1000 copies), which return to undetectable 98 
without any intervention. (18, 19). This study evaluated the accuracy and performance of 99 
the SAMBA HIV-1 Semi-Q Test with a cut-off of 1000 copies/ml compared to gold 100 
standard viral load testing. 101 
 102 
Methods 103 
Determination of VL with SAMBA HIV-1 Semi-Q  104 
RNA was extracted from 200 µl of plasma using the SAMBA sample-preparation 105 
instrument, SAMBAprep (Figure 1A). The result was read visually after isothermal 106 
amplification and dipstick detection within the SAMBAamp instrument (Figure 1A). The 107 
presence of a control line indicates a valid test and the test line on the dipstick indicates a 108 
VL of >1000 copies/ml, whereas the absence of the test line indicates a VL of <1000 109 
copies/ml. The absence of both lines indicates an invalid test (Figure 1B). This assay does 110 
not detect HIV-2 and should not be used for diagnosis of HIV-1 infection. 111 
 112 
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Preparation of dilution panels of HIV-1 subtype C samples for validation of the 113 
SAMBA HIV-1 Semi-Q cut-off of 1000 copies/ml 114 
We obtained four surplus samples from blood donors identified as positive for antibodies to 115 
HIV-1 from the National Blood Transfusion Centre in Windhoek, Namibia. Viral 116 
genotyping and VL quantification of the samples with the Roche COBAS 117 
AmpliPrep/COBAS TaqMan HIV-1 Test v2·0 (Roche TaqMan v2) were performed at The 118 
Royal London Hospital. Serial 2-10 fold dilutions of the four samples were prepared in 119 
HIV-negative plasma to achieve HIV-1 RNA concentrations ranging from 3 (0.48 log10) to 120 
222,238 (5.35 log10) copies/ml according to the quantification by Roche TaqMan v2. Four 121 
replicates of each dilution were tested with the SAMBA HIV-1 Semi-Q by two operators 122 
in-house to assess the precision and accuracy of the test. A total of 96 dilutions were tested. 123 
 124 
Data analysis 125 
The limit of accuracy for Roche TaqMan v2 is ±0.3 log10 relative to the VL readout 126 
obtained, according to the package insert. For the purpose of the present study, we therefore 127 
considered that any VL quantification by Roche TaqMan v2 within 0.3 log10 of the 128 
SAMBA HIV-1 Semi-Q cut-off of 1000 (3 log10) copies/ml, corresponding to a range of 129 
500 to 2000 copies/ml, was concordant with the SAMBA HIV-1 Semi-Q result. 130 
 131 
In-house blinded testing of clinical samples  132 
Plasma samples from 134 HIV-1–infected individuals attending The Royal London 133 
Hospital (34 patients) or St Thomas’ Hospital (100 patients) in London were rendered 134 
anonymous and provided blinded. The plasma samples were stored at –80°C until tested in-135 
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house with the SAMBA HIV-1 Semi-Q Test. Roche TaqMan v2 results and HIV-1 subtype 136 
information (if available) were provided by both hospitals after the SAMBA HIV-1 Semi-Q 137 
testing was completed. In addition, two EQA subtype panels from Rush University 138 
RNA004XPA and RNA004XPB, containing 84 samples per panel including subtypes A, 139 
A/E, A/G, C, D, F and G at 2,500 and 25,000 copies/ml were tested blinded in-house. 140 
 141 
Field-testing of SAMBA HIV-1 Semi-Q in Malawi and Uganda 142 
Field-testing of the SAMBA HIV-1 Semi-Q Test was performed at ART provision program 143 
centers run by MSF in Malawi (Chiradzulu District Hospital) and Uganda (Arua Regional 144 
Referral Hospital). The Chiradzulu HIV program, which was established in 2000 and 145 
currently monitors 25,000 patients on ART, has been described in detail previously.(20, 21) 146 
The HIV program in Arua was established in 2002 and follows 7000 HIV-infected 147 
individuals on ART.(22) 148 
 149 
Samples were collected both from consecutive patients attending the HIV clinics, on ART 150 
and pre-ART patients, in order to obtain a wide range of VLs. Plasma was separated from 151 
whole blood specimens (10 ml) within 4 hours of collection and tested fresh. In Malawi, the 152 
first 117 samples were sent to Cambridge for testing while the local technician was trained. 153 
The remaining 83 samples were tested on-site by a trained MSF technician. In Uganda, the 154 
first 120 samples collected were tested on-site by the MSF technician, and the remaining 34 155 
samples were shipped to Cambridge for testing due to time constraints. All 354 samples 156 
from Malawi and Uganda were tested with Roche TaqMan v2 at The Royal London 157 
Hospital. In the case of discrepancy between Roche TaqMan v2 and SAMBA Semi-Q, 158 
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remaining frozen plasma was tested using Abbott RealTime HIV-1 Assay (Abbott 159 
RealTime) by an independent laboratory. 160 
 161 
Analysis of VL distribution among patients in Malawi and Uganda according to 162 
available clinical information 163 
Patient records were accessed, after consent was obtained, for the 354 patients in Malawi 164 
and Uganda and were analyzed after all testing was complete. The VL of the 284 treated 165 
patients was compared with that of the 70 treatment-naïve individuals in order to determine 166 
the VL spread. In addition, the VL of 232 patients on ART for 0.5 to 9 years was stratified 167 
according to treatment duration and used to compare the number of individuals defined as 168 
virologically suppressed according either to the 2010 WHO guidelines or to the SAMBA 169 
HIV-1 Semi-Q cut-off. 170 
 171 
Research ethics 172 
The study was performed in accordance with the Declaration of Helsinki. Ethical approval 173 
was obtained from the National Health Sciences Research Committee, Ministry of Health 174 
and Population, for Chiradzulu Hospital (Malawi), from the Uganda National Council for 175 
Science and Technology for Arua District Hospital (Uganda), and from the Research Ethics 176 
Committee, NRES-London, for St Thomas’ Hospital (United Kingdom). Nucleic acid 177 
testing of blood donor samples is approved in Namibia, and the four donors in the present 178 
study were informed of potential additional testing. Surplus samples obtained from patients 179 
known to be infected with HIV-1 and submitted to The Royal London Hospital for routine 180 
monitoring were retrieved before being discarded, rendered anonymous and provided 181 
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blinded for the purpose of test validation; the use of samples in this manner, strictly for the 182 
purpose of diagnostic assay validation, does not fall under the requirements of research 183 
ethics for the organizations in which they originated.  184 
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Results 185 
Validation of the accuracy of the SAMBA HIV-1 Semi-Q cut-off 186 
All 52 dilutions of the four Namibian samples (all HIV-1 subtype C) containing >1000 187 
(>3.0 log10) copies/ml according to Roche TaqMan v2 were correctly identified as such 188 
with SAMBA Semi-Q, and 43 of 44 (98%) dilutions containing <1000 copies/ml according 189 
to Roche TaqMan v2 were similarly correctly identified by SAMBA Semi-Q (Table 1). 190 
One of the dilutions that tested negative by SAMBA Semi-Q but according to Roche 191 
TaqMan v2 should contain 1211 (3·08 log10) copies/ml and two of the dilutions found to be 192 
positive by SAMBA Semi-Q that should contain 606 (2·78 log10) copies/ml according to 193 
Roche TaqMan v2 were considered concordant because of the accuracy limits of the 194 
TaqMan assay (see Methods). Therefore, the overall concordance between SAMBA HIV-1 195 
Semi-Q and Roche TaqMan v2 for these 96 sample dilutions was 99% (95/96; 95% CI, 196 
93.8–99.9). 197 
 198 
Specificity  199 
The specificity of the SAMBA HIV-1 assay was evaluated by testing 216 HIV-1 200 
seronegative plasma patient specimens. The assay was not reactive for all 216 specimens 201 
and the SAMBA HIV-1 assay specificity was calculated to be 100% (216/216), (95% CI 202 
98.6 to 100%). The specificity of the SAMBA HIV-1 Test was further evaluated using a 203 
panel of 43 specimens obtained from samples containing the following viruses, 204 
microrganisms or antibodies from autoimmune disorders: Hepatitis A (2 samples), 205 
Hepatitis B (24 samples), Hepatitis C (3 samples), CMV (2 samples) and 1 sample of each 206 
of HIV-2, HTLV I, HTLV II, Syphilis, anti-nuclear antibodies (ANA), Chlamydia 207 
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trachomatis, Neisseria gonorrhoeae, Propiobacterium acnes, Staphylococcus aureus, 208 
Candida albicans, Staphylococcus epidermis, Streptococcus pyogenes. All tested negative 209 
by SAMBA. 210 
 211 
Potentially interfering substances 212 
The susceptibility of the SAMBA Semi-Q test to interference by elevated levels of 213 
endogenous substances and drugs commonly prescribed to HIV-1 infected individuals was 214 
evaluated. HIV-1 negative samples and samples containing 1,000 and 2,000 IU/ml of HIV-215 
1 RNA were tested in the presence of the following substances: Hemoglobin (500 mg/dL), 216 
Triglycerides (3000 mg/dL), Bilirubin (20 mg/dL) and Human DNA (0.4 mg/dL). No 217 
interference in the performance of the SAMBA Semi-Q test was observed. Testing of ART 218 
drugs at concentrations in excess of 1.5 times the peak plasma level (Cmax) was performed 219 
using the following: Abacavir/Lamivudine, Efavirenz/Tenofovir/Emtricitabine, 220 
Lopinavir/Ritonavir, Lamivudine/Zidovudine, Nevirapine, Ribavirin and Saquinavir. No 221 
interference on the performance of the SAMBA Semi-Q test was observed. 222 
 223 
In-house blinded testing of clinical samples  224 
A total of 134 HIV-1–positive plasma samples from 100 male and 34 female patients 225 
attending two London hospitals were tested with the SAMBA HIV-1 Semi-Q Test in a 226 
blinded manner in-house. SAMBA Semi-Q was concordant with Roche TaqMan v2 for 131 227 
of the 134 samples when four specimens (VL of 800, 948, 1285, and 1507 copies/ml 228 
respectively) were considered concordant because of the accuracy limits of the TaqMan 229 
assay (Table 2). One of 35 samples found to contain >2000 (3.3 log10) copies/ml by Roche 230 
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TaqMan v2 was negative by SAMBA Semi-Q (2508 copies/ml), and 2 of 95 samples found 231 
to contain <500 (2.7 log10) copies/ml by the Roche TaqMan assay tested positive by 232 
SAMBA Semi-Q (53 and 252 copies/ml). The concordance between SAMBA HIV-1 Semi-233 
Q and Roche TaqMan v2 was thus 97.8% (131/134; 95% CI, 93.3–99.5). Viral subtype data 234 
provided for 76 of these samples after the SAMBA HIV-1 Semi-Q testing was completed 235 
revealed a distribution of 44.7% subtype B; 18.4% C; 10.5% CRF02_AG; 5.3% A; 2.6% 236 
CRF01_AE, F, G, G/CRF02_AG, CRF11_cpx/CRF13_cpx and A/AE; 1.3% D, 237 
CRF06_cpx, D/A and D/F. The subtypes for only two of the three discrepant samples (B 238 
and A/D) were available. In addition, a blinded EQA subtype panel provided by Rush 239 
University was tested and all 168 samples (84 at 2,500 and 84 at 25,000 copies.ml), 240 
including subtypes A, CRF01_AE, CRF02_AG, C, D, F and G, were successfully detected 241 
by SAMBA. 242 
 243 
Field-testing of SAMBA HIV-1 Semi-Q in Malawi and Uganda 244 
A total of 200 samples collected in Chiradzulu, Malawi, were from 72 men and 128 245 
women, with the patients ranging in age from 18 to 61 years. Four patients were assigned 246 
an ID but withdrew from the study with no sample being collected. The 154 samples 247 
collected in Arua, Uganda, were from 68 men and 86 women, with ages ranging from 18 to 248 
71 years. Overall, 70 patients (19.8%) were ART naïve and 284 (80.2%) had been on ART 249 
for a period of 1 month to 10 years at the time of testing.  250 
 251 
A total of 196 of the 200 samples collected in Malawi were correctly classified by SAMBA 252 
HIV-1 Semi-Q (Table 2), with five samples (VLs of 601, 651, 922, 1539, and 1599 253 
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copies/ml) being included as concordant because of the accuracy limits of Roche TaqMan 254 
v2. For Uganda, 146 of the 154 samples were concordant between SAMBA HIV-1 Semi-Q 255 
and Roche TaqMan v2, with one sample (VL of 1061 copies/ml) being classified as such as 256 
a result of the accuracy limits of the TaqMan assay. The concordance between SAMBA 257 
HIV-1 Semi-Q and Roche TaqMan v2 was thus 96.6% overall, 98.0% in Malawi, and 258 
94.8% in Uganda (Table 2).  259 
 260 
Taking into consideration all data, 18 samples (5%) were discrepant between SAMBA and 261 
Roche, including six samples within the ±0.3 log10 of the SAMBA Semi-Q cut-off. Twelve 262 
of the 354 samples (3.4%) were truly discordant, with a VL outside of the ±0.3 log10 263 
accuracy of the SAMBA Semi-Q cut-off. These 12 samples (four from Malawi and eight 264 
from Uganda) included seven found to contain <500 (2.7 log10) copies/ml and five found to 265 
contain >2000 (3.3 log10) copies/ml by Roche TaqMan v2 (Figure 2 and Table 2). These 12 266 
discordant samples were retested with Abbott RealTime at one of two independent 267 
laboratories and in a blinded manner with regard to the SAMBA HIV-1 Semi-Q and Roche 268 
TaqMan v2 results. The Abbott RealTime results were concordant with the Roche TaqMan 269 
v2 results for 10 of the 12 samples (Figure 2). Two of the original five discrepant samples 270 
found to contain >2000 (3.3 log10) copies/ml by Roche TaqMan v2 were found to contain 271 
<1000 copies/ml by Abbott RealTime. 272 
 273 
 Analysis of VL distribution among African patients according to available clinical 274 
information 275 
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The VL of the 284 treated patients from Malawi and Uganda ranged from 0 to 2.6 × 106 276 
copies/ml, whereas that of the 70 treatment-naïve individuals ranged from 1.2 × 102 to >1.0 277 
x 107 copies/ml (Figure 3). In both Malawi and Uganda, the SAMBA Semi-Q cut-off value 278 
of 1000 copies/ml clearly separated individuals in the untreated group from those in the 279 
treated group. 280 
 281 
The VL results obtained with Roche TaqMan v2 for 232 patients on ART for 0.5 to 9 years 282 
were stratified according to duration of therapy, and virological suppression was defined as 283 
either <1000 copies/ml (SAMBA HIV-1 Semi-Q cut-off) or <5000 copies/ml (2010 WHO 284 
guidelines) (Figure 4). With either definition, 93.8% of individuals manifested virological 285 
suppression after 0.5 to 1 year on treatment. The percentage of individuals with suppression 286 
fluctuated between 80.6 and 96.0% (1000 copies/ml definition) or between 83.9 and 96.0% 287 
(5000 copies/ml definition) for treatment durations of 1 to 9 years. Similar results were 288 
obtained with the two definitions of virological suppression because only six individuals 289 
(2.6%) on treatment for 0.5 to 9 years had a VL between these two values. 290 
 291 
Discussion 292 
The SAMBA HIV-1 Semi-Q cut-off was validated for accuracy in comparison with the 293 
Roche TaqMan v2 test with the use both of diluted clinical samples and of blinded plasma 294 
samples in-house and in the field in two public-sector ART provision programs in Africa. 295 
This study demonstrated that the SAMBA HIV-1 Semi-Q Test is able to effectively 296 
differentiate between patients with a VL above or below the defined threshold of 1000 297 
copies/ml. The current gold-standard VL assays have a given accuracy acceptance criterion 298 
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of ±0.3 log10 for Roche TaqMan v2 and ±0.25 log10 for Abbott RealTime relative to the 299 
nominal input concentration.(23) For the present evaluations, we selected Roche TaqMan 300 
v2 as the gold standard as it is more widely used. Any samples found to contain 500 to 301 
2000 (2.7 log10 to 3.3 log10) copies/ml by this assay were therefore considered concordant 302 
with the SAMBA result, given that the true VL might lie on either side of the cut-off. A 303 
dilution series for four samples containing HIV-1 subtype C tested by two operators 304 
revealed excellent concordance (99.0%). The subtype coverage of SAMBA was evaluated 305 
using a blinded EQA panel from Rush University, which SAMBA detected 100% of the 306 
samples including subtype A, CRF01_AE, CRF02_AG, C, D, F and G. The SAMBA HIV-307 
1 Semi-Q cut-off was further validated in-house with a blinded panel of clinical samples, 308 
including HIV-1 subtypes A–G and a range of recombinants, yielding an accuracy of 309 
97.8%, showing that the accuracy extends over a wide variety of viral subtypes. The 310 
reproducibility and accuracy of the SAMBA HIV-1 Semi-Q Test with fresh clinical 311 
samples collected in the field were evaluated by a trained field technician in each of two 312 
public-sector ART provision programs in Malawi and Uganda. The data were again 313 
compared with Roche TaqMan v2 results, revealing an overall concordance of 96.6%. In 314 
total, the concordance of SAMBA HIV-1 Semi-Q with Roche TaqMan v2 as determined 315 
with clinical samples from London and Africa was 97.3% (568/584; 95% confidence 316 
interval, 95.6–98.3), indicating that the performance of the SAMBA HIV-1 Semi-Q Test is 317 
in line with that of the available commercial assays. Importantly, SAMBA Semi-Q was 318 
performed on-site in Malawi and Uganda by trained MSF technicians, showing that it is 319 
simple enough to serve as an appropriate diagnostic platform for use in district hospitals in 320 
sub-Saharan Africa.  321 
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 322 
Our data suggest that SAMBA HIV-1 Semi-Q, with its cut-off of 1000 (3 log10) copies/ml, 323 
is likely to prove a useful tool for assessment of the efficacy of ART and for identifying 324 
patients either who have developed virological failure and possible antiretroviral resistance 325 
or who have been infected with a drug-resistant strain of HIV-1. This cut-off level should 326 
also help to minimize unnecessary treatment switching due to viral blips. In addition, given 327 
that the test can be performed in the field within 90 minutes, the patient can remain on-site 328 
and appropriate action can be taken during the same visit. This is hugely beneficial, given 329 
the fact that patients frequently face very long journeys to and from the health centers.  In 330 
Khayelitsha, South Africa, the ability of ART to reduce VL to an undetectable level was 331 
found to correlate with the timing of viral detection and the subsequent treatment adherence 332 
support provided. [4] The availability of an easy-to-use, semi-quantitative, and inexpensive 333 
rapid test to detect virological failure would therefore be expected to make an important 334 
contribution to optimization of first- and second-line treatment in resource constrained 335 
countries. (7) 336 
 337 
Our analysis of VL distribution in African patients indicated that the SAMBA HIV-1 Semi-338 
Q cut-off is able to reliably differentiate patients on effective ART from non-treated 339 
patients as well as identifying patients with virological failure according to current WHO 340 
guidelines. Analysis of the VL of 232 patients on ART for 0.5 to 9 years showed that the 341 
temporal pattern for virological failure as defined in the SAMBA HIV-1 Semi-Q model and 342 
current WHO guideline (>1000 copies/ml) was highly similar to that observed with the 343 
2010 WHO guidelines (>5000 copies/ml).  344 
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 345 
One key advantage of the SAMBA system is that it relies on visual detection of nucleic 346 
acid on a test strip, with a readout similar to that of an HIV antibody rapid test. The 347 
processed test strip can be shown to the patient as a reinforcement tool. However, although 348 
the difference in signal strengths between positive and negative results for SAMBA HIV-1 349 
Semi-Q is greater than that seen with many rapid tests, there remains the possibility of 350 
transcription errors or misinterpretation of results by operators in the field. This limitation 351 
will be overcome by the development of SAMBA 2, a fully integrated system in the form 352 
of a small bench-top instrument, into which the sample is introduced and the result appears 353 
on a screen or be printed on paper. 354 
 355 
SAMBA HIV-1 Semi-Q is a semi-quantitative test for differentiation between patients with 356 
a VL above or below 1000 copies/ml, which may be regarded as a limitation of the assay 357 
given that currently available commercial tests provide a numerical readout. Although these 358 
readouts appear accurate, the accuracy of the results differs between tests, being ±0.3 log10 359 
for Roche TaqMan v2 and ±0.25 log10 for Abbott RealTime. Furthermore, the Abbott assay 360 
consistently reads lower than the Roche test, (23) which was apparent in our analysis of 361 
discrepant samples. These VL numbers can be useful for tracking the initial virological 362 
response of individuals to treatment and are routinely reported to patients in industrialized 363 
countries. However, in LMICs, where mass treatment-monitoring is required but is 364 
currently not available, the main need of the clinician is to identify individuals who are not 365 
responding to treatment and act accordingly as soon as possible. MSF have implemented 366 
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SAMBA Semi-Q for routine use at one site in Arua and two sites in Chiradzulu since 367 
August 2013. Patients are monitored twice per year and results are given at the same visit. 368 
Those with a VL >1000 copies/ml are counseled for adherence reinforcement and if they 369 
still have a viral load >1000 copies/ml at the next visit they are switched to second-line 370 
therapy.  371 
372 
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Table 1. Validation of the SAMBA HIV-1 Semi-Q cut-off with diluted plasma samples 461 
containing HIV-1 subtype C.  462 
 463 
Sample 
HIV-1 RNA 
(copies/ml) 
Positive SAMBA HIV-1 Semi-Q 
result (>1,000 copies/ml) 
1 
151,114 100% 
15,111 100% 
1511 100% 
756 0% 
151 0% 
15 0% 
2 
30,543 100% 
3054 100% 
1527 100% 
305 0% 
31 0% 
3 0% 
3 
222,238 100% 
22,224 100% 
2222 100% 
1111 100% 
222 25% 
25 
 
 
22 0% 
4 
121,102 100% 
12,110 100% 
1211 75% 
606 50% 
121 0% 
12 0% 
 464 
Four plasma samples were serially diluted to achieve concentrations of viral RNA ranging 465 
from 3 (0·48 log10) to 222,238 (5·35 log10) copies/ml according to quantification with 466 
Roche TaqMan v2. Four replicates of each dilution were tested with SAMBA HIV-1 Semi-467 
Q.  468 
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Table 2. Comparison of SAMBA HIV-1 Semi-Q and Roche TaqMan v2 results for 488 469 
clinical samples from London (n=134), Malawi (n =200) and Uganda (n = 154).  470 
 471 
SAMBA Semi-Q 
(copies/ml) 
Roche TaqMan v2 (copies/ml) 
 
London 
 
<1000 
 
>1000 
<1000 95 1 
>1000 2 36 
 
Malawi 
  
<1000 146 0 
>1000 4 50 
 
Uganda 
  
<1000 91 5 
>1000 3 55 
 472 
Concordance between the two tests was 96.9% (473/488) overall, 97.8% (131/134) in 473 
London, 98.0% (196/200) in Malawi, and 94.8% (146/154) in Uganda. 474 
 475 
 476 
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Figure 1: SAMBA I system 477 
A. SAMBA I instruments, SAMBAprep (right) and SAMBAamp (left) instruments 478 
B. SAMBAamp cartridge showing results for (i) >1,000 copies/ml, (ii) < 1,000 copies/ml 479 
and (iii) invalid. 480 
 481 
Figure 2. Field-testing algorithm for SAMBA HIV-1 Semi-Q with 354 samples collected in 482 
Malawi and Uganda and summary of results. All samples were tested with SAMBA HIV-1 483 
Semi-Q and Roche TaqMan v2. Twelve samples were discrepant between SAMBA and 484 
Roche and were tested with Abbott RealTime. Ten of the twelve samples were discrepant 485 
between SAMBA and Abbott, two were discrepant between Abbott and Roche.  486 
 487 
Figure 3. Distribution of VL among 284 patients receiving ART and 70 untreated 488 
individuals in Malawi and Uganda. VL was determined with Roche TaqMan v2. 489 
 490 
Figure 4. Virological suppression according to the SAMBA HIV-1 Semi-Q cut-off and 491 
2013 WHO guidelines (1000 copies/ml) or 2010 WHO guidelines (5000 copies/ml) in 232 492 
patients on ART for various number of years in Uganda and Malawi.  493 
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